Johnson & Johnson’s Rybrevant Faspro combination shows 77% response rate in head and neck cancer trial

• Johnson & Johnson reported sustained tumor responses with Rybrevant Faspro combined with pembrolizumab and carboplatin in first-line advanced head and neck cancer.
• Responses were strongest in patients without HPV-associated oropharyngeal cancer; safety was consistent with the individual drugs.
• The Phase 1b/2 OrigAMI-4 results were presented at the European Society for Medical Oncology Congress 2026, supporting the ongoing Phase 3 OrigAMI-5 study.
• A separate application for Rybrevant Faspro in later-line head and neck cancer is under FDA priority review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610250945PR_NEWS_USPR_____NY80367) on October 25, 2026, and is solely responsible for the information contained therein.